Glomerular pathology in Alport syndrome: A molecular perspective

Research output: Contribution to journalReview article

24 Citations (Scopus)

Abstract

We have known for some time that mutations in the genes encoding 3 of the 6 type IV collagen chains are the underlying defect responsible for both X-linked (where the COL4A5 gene is involved) and autosomal (where either COL4A3 or COL4A4 genes are involved) Alport syndrome. The result of these mutations is the absence of the sub-epithelial network of all three chains in the glomerular basement membrane (GBM), resulting, at maturity, in a type IV collagen GBM network comprising only α1(IV) and α2(IV) chains. The altered GBM functions adequately in early life. Eventually, there is onset of proteinuria associated with the classic and progressive irregular thickening, thinning, and splitting of the GBM, which culminates in end-stage renal failure. We have learned much about the molecular events associated with disease onset and progression through the study of animal models for Alport syndrome, and have identified some potential therapeutic approaches that may serve to delay the onset or slow the progression of the disease. This review focuses on where we are in our understanding of the disease, where we need to go to understand the molecular triggers that set the process in motion, and what emergent therapeutic approaches show promise for ameliorating disease progression in the clinic.

Original languageEnglish (US)
Pages (from-to)885-890
Number of pages6
JournalPediatric Nephrology
Volume27
Issue number6
DOIs
StatePublished - Jun 1 2012

Fingerprint

Hereditary Nephritis
Glomerular Basement Membrane
Pathology
Disease Progression
Collagen Type VI
X-Linked Genes
Mutation
Collagen Type IV
Proteinuria
Genes
Chronic Kidney Failure
Animal Models
Therapeutics

Keywords

  • Alport syndrome
  • Glomerular basement membrane
  • Pathobiology
  • Podocyte

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Nephrology

Cite this

Glomerular pathology in Alport syndrome : A molecular perspective. / Cosgrove, Dominic E.

In: Pediatric Nephrology, Vol. 27, No. 6, 01.06.2012, p. 885-890.

Research output: Contribution to journalReview article

@article{7c248a75ce3d4448872d5860a9deeb7e,
title = "Glomerular pathology in Alport syndrome: A molecular perspective",
abstract = "We have known for some time that mutations in the genes encoding 3 of the 6 type IV collagen chains are the underlying defect responsible for both X-linked (where the COL4A5 gene is involved) and autosomal (where either COL4A3 or COL4A4 genes are involved) Alport syndrome. The result of these mutations is the absence of the sub-epithelial network of all three chains in the glomerular basement membrane (GBM), resulting, at maturity, in a type IV collagen GBM network comprising only α1(IV) and α2(IV) chains. The altered GBM functions adequately in early life. Eventually, there is onset of proteinuria associated with the classic and progressive irregular thickening, thinning, and splitting of the GBM, which culminates in end-stage renal failure. We have learned much about the molecular events associated with disease onset and progression through the study of animal models for Alport syndrome, and have identified some potential therapeutic approaches that may serve to delay the onset or slow the progression of the disease. This review focuses on where we are in our understanding of the disease, where we need to go to understand the molecular triggers that set the process in motion, and what emergent therapeutic approaches show promise for ameliorating disease progression in the clinic.",
keywords = "Alport syndrome, Glomerular basement membrane, Pathobiology, Podocyte",
author = "Cosgrove, {Dominic E}",
year = "2012",
month = "6",
day = "1",
doi = "10.1007/s00467-011-1868-z",
language = "English (US)",
volume = "27",
pages = "885--890",
journal = "Pediatric Nephrology",
issn = "0931-041X",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Glomerular pathology in Alport syndrome

T2 - A molecular perspective

AU - Cosgrove, Dominic E

PY - 2012/6/1

Y1 - 2012/6/1

N2 - We have known for some time that mutations in the genes encoding 3 of the 6 type IV collagen chains are the underlying defect responsible for both X-linked (where the COL4A5 gene is involved) and autosomal (where either COL4A3 or COL4A4 genes are involved) Alport syndrome. The result of these mutations is the absence of the sub-epithelial network of all three chains in the glomerular basement membrane (GBM), resulting, at maturity, in a type IV collagen GBM network comprising only α1(IV) and α2(IV) chains. The altered GBM functions adequately in early life. Eventually, there is onset of proteinuria associated with the classic and progressive irregular thickening, thinning, and splitting of the GBM, which culminates in end-stage renal failure. We have learned much about the molecular events associated with disease onset and progression through the study of animal models for Alport syndrome, and have identified some potential therapeutic approaches that may serve to delay the onset or slow the progression of the disease. This review focuses on where we are in our understanding of the disease, where we need to go to understand the molecular triggers that set the process in motion, and what emergent therapeutic approaches show promise for ameliorating disease progression in the clinic.

AB - We have known for some time that mutations in the genes encoding 3 of the 6 type IV collagen chains are the underlying defect responsible for both X-linked (where the COL4A5 gene is involved) and autosomal (where either COL4A3 or COL4A4 genes are involved) Alport syndrome. The result of these mutations is the absence of the sub-epithelial network of all three chains in the glomerular basement membrane (GBM), resulting, at maturity, in a type IV collagen GBM network comprising only α1(IV) and α2(IV) chains. The altered GBM functions adequately in early life. Eventually, there is onset of proteinuria associated with the classic and progressive irregular thickening, thinning, and splitting of the GBM, which culminates in end-stage renal failure. We have learned much about the molecular events associated with disease onset and progression through the study of animal models for Alport syndrome, and have identified some potential therapeutic approaches that may serve to delay the onset or slow the progression of the disease. This review focuses on where we are in our understanding of the disease, where we need to go to understand the molecular triggers that set the process in motion, and what emergent therapeutic approaches show promise for ameliorating disease progression in the clinic.

KW - Alport syndrome

KW - Glomerular basement membrane

KW - Pathobiology

KW - Podocyte

UR - http://www.scopus.com/inward/record.url?scp=84863983649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863983649&partnerID=8YFLogxK

U2 - 10.1007/s00467-011-1868-z

DO - 10.1007/s00467-011-1868-z

M3 - Review article

C2 - 21455721

AN - SCOPUS:84863983649

VL - 27

SP - 885

EP - 890

JO - Pediatric Nephrology

JF - Pediatric Nephrology

SN - 0931-041X

IS - 6

ER -